Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDX3X | O00571 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.59 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | MMP1 | P03956 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | MMP8 | P22894 | 1/20 | 0.52 |
| ▸ | MMP13 | P45452 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | NFKBIA | P25963 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7489637 | 0.88 | KMT2A (0.64) | DDX3XKMT2AMEN1CXCR1CXCR2 | |
| SCHEMBL7488767 | 0.81 | KMT2A (0.56) | DDX3XKMT2AMEN1CXCR1CXCR2 | |
| SCHEMBL7494404 | 0.81 | POLB (0.51) | DDX3XKMT2AMEN1CXCR1CXCR2 | |
| SCHEMBL7491487 | 0.78 | MEN1 (0.67) | DDX3XKMT2AMEN1CXCR1CXCR2 | |
| SCHEMBL11863940 | 0.78 | DDX3X (1.00) | DDX3XKMT2AMEN1CYP3A4CYP2C9 | |
| SCHEMBL5467045 | 0.76 | DDX3X (0.69) | DDX3XKMT2AMEN1CYP3A4CYP2C9 | |
| SCHEMBL7557478 | 0.76 | CXCR2 (0.53) | KMT2AMEN1CXCR1CXCR2CA1 | |
| SCHEMBL12768396 | 0.76 | KMT2A (0.65) | DDX3XKMT2AMEN1CYP3A4CYP2C9 | |
| SCHEMBL5467385 | 0.75 | DDX3X (0.71) | DDX3XKMT2AMEN1CA1CA2 | |
| SCHEMBL5460836 | 0.75 | DDX3X (0.71) | DDX3XKMT2AMEN1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6211373-B1 | Phenyl urea antagonists of the IL-8 receptor | SMITHKLINE BEECHAM CORPORATION | 2001-04-03 | — | — | US | claimed |
| EP-0809492-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2007-01-24 | — | — | EP | disclosed |
| EP-1185261-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-02-25 | — | — | EP | disclosed |
| EP-0896531-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020128321-A1 | IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-09-12 | — | — | US | disclosed |
| EP-1185261-A1 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2002-03-13 | — | — | EP | disclosed |
| US-6262113-B1 | HYDROXY- OR MERCAPTO-PHENYLUREAS | SMITHKLINE BEECHAM CORPORATION | 2001-07-17 | — | — | US | disclosed |
| US-6211373-B1 | Phenyl urea antagonists of the IL-8 receptor | SMITHKLINE BEECHAM CORPORATION | 2001-04-03 | — | — | US | disclosed |
| US-6180675-B1 | THERAPY FOR CHEMOKINE SENSITIVE DISEASE; USING A AROMATIC (THIO)UREA COMPOUND | SMITHKLINE BEECHAM CORPORATION | 2001-01-30 | — | — | US | disclosed |
| WO-2000076495-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-12-21 | — | — | WO | disclosed |
| US-6005008-A | IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-21 | — | — | US | disclosed |
| US-5886044-A | IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1999-03-23 | — | — | US | disclosed |
| EP-0896531-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-17 | — | — | EP | disclosed |
| US-5780483-A | IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1998-07-14 | — | — | US | disclosed |
| EP-0809492-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-12-03 | — | — | EP | disclosed |
| WO-1997029743-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-08-21 | — | — | WO | disclosed |
| WO-1996025157-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128321-A1 | IL-8 receptor antagonists | CXCL8, CCR8, IL1RN | DDX3X 3894/4885KMT2A 3978/4885MEN1 4754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.